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INTRODUCTION
Infections caused by the hepatitis C virus (HCV) are 
currently a serious public health problem. It is estimated that 
3 to 4 million new cases occur worldwide every year. Of the 
individuals with acute HCV infections, 55% to 85% will be 
chronically infected and will thus be at risk of liver damage, 
cirrhosis and hepatocellular carcinoma.1,2 In total, more than 
170 million people (i.e., ≈2% of the world’s population) are 
infected with HCV. The best treatment currently available is 
a combination of pegylated interferon and ribavirin.2–6
Interferons are potent cytokines with antiviral, 
antiproliferative and immunomodulatory activities.7 
Interferons are linked to cell surface receptors and cause 
a cascade of intracellular events, including the induction 
of the transcription of genes that inhibit cell growth and of 
genes that alter cell differentiation, oncogene expression 
and the expression of antigens on the cell surface. In turn, 
these effects increase macrophage phagocytosis and the 
cytotoxicity of lymphocytes in relation to target cells and 
hinder mechanisms of viral replication in parasitic cells. 
The treatment of hepatitis C has various limitations: cost, 
efficacy and, principally, adverse effects. The numerous side 
effects observed range from the trivial, such as influenza-like 
symptoms, anorexia, fatigue, headache, nausea myalgia, 
diarrhea, local reactions to the application of the medication, 
alopecia and pruriginous rash, to the severe, such as 
psychiatric symptoms, cytopenias and respiratory symptoms 
(cough and dyspnea). Among the rarest and most potentially 
deleterious adverse manifestations are pancreatitis, profound 
medullary depression and cardiotoxicity, which can lead to 
cardiac failure and sudden death.2,3,8,9 Finally, it has been 
suggested that interferon alpha therapy is associated with 
the development and exacerbation of autoimmune diseases.3
Severe lung toxicity is associated with interferon alpha 
monotherapy as well as combination therapies involving 
ribavirin and conventional or pegylated interferon alpha. There 
have also been reported cases of interstitial pneumonia,2,10 
bronchiolitis obliterans organizing pneumonia (BOOP), 
sarcoidosis and severe profiles of asthma exacerbation.9 
For example, Kuno et al. described three cases involving 
patients with chronic hepatitis C who developed interstitial 
pneumonitis during treatment with interferon alpha and 
presented complete resolution of the symptoms after 
discontinuation of the medication.11 Nevertheless, pulmonary 
complications associated with interferon alpha therapy 
are rare. In the literature, the pathology most commonly 
associated with interferon alpha therapy is interstitial 
pneumonitis, followed by sarcoidosis-like conditions leading 
to the formation of noncaseating granulomas.3,7,8
Ribavirin is a purinic nucleoside analog with a modified 
base and a D-ribose sugar. Although the mechanisms of 
ribavirin action continue to be the object of speculation, it is 
possible that ribavirin acts as an immunostimulating antiviral 
agent and has recently been proposed to be a stimulator of 
inducible interferon genes.12 When combined with interferon 
alpha, ribavirin contributes greatly to obtaining a sustained 
virological response (SVR) and to reducing recurrence. 
Ribavirin side effects are hemolytic anemia, fatigue, rash and 
cough. However, there have been no reports of severe cases 
or cases with pronounced symptoms.
CASE REPORT
A 53-year-old white man who was a former intravenous 
746
CLINICS 2010;65(7):745-8Peginterferon-related bronchial casts
Araújo ESA et al.
Copyright © 2010 CLINICS
drug user and who had a history of stable diabetes mellitus 
and smoking (82 pack-years) sought treatment after 
having recently been diagnosed with chronic hepatitis C. 
A hepatic biopsy, conducted in February of 2006, revealed 
histological alterations consistent with cirrhosis (METAVIR 
fibrosis score and activity score, F4 and A3). Virological 
tests at baseline showed infection with genotype 3a and a 
viral load of 780,203 IU/mL (COBAS Amplicor®; Roche 
Molecular Diagnostics, Basel, Switzerland). In July of 
2006, treatment with a combination of pegylated interferon 
alpha-2a (Pegasys®; Roche) and ribavirin (180 µg/week 
and 1000 mg/day, respectively) was initiated. After 12 
weeks of treatment, the patient presented dyspnea on 
extreme exertion, with episodes of cough followed by 
voluminous expectoration consisting of large pieces (up 
to 8.0 cm in length) of mucus-like material mimicking 
bronchial casts (Figs. 1a and 1b). Expectoration occurred 
daily, mainly during the night, and was exacerbated by 
a cold environment. The patient did not present fever, 
night sweats, orthopnea or paroxysmal nocturnal dyspnea. 
Considering the good virological response to the treatment 
(HCV RNA not detected at week 12 of therapy, which is 
indicative of complete early virological response (cEVR)) 
and the severity of the hepatic impairment, together with 
the willingness of the patient to continue, we opted for 
not interrupting the treatment. Empirically, we employed 
anti-inflammatory treatment with prednisone (40 mg/
day). Partial improvement was obtained, and the dose was 
tapered to the lowest possible level that would suppress the 
symptoms, being increased when necessary. Therefore, there 
was no symptom progression, and the exacerbations were 
controlled. Despite the pulmonary profile and the cEVR, but 
given the use of high doses of prednisone, the severity of the 
hepatic histological lesion and the high baseline viral load, 
we decided to maintain the therapy with pegylated interferon 
alpha and ribavirin for 48 weeks. Immediately after the use 
of pegylated interferon and ribavirin was discontinued, there 
was complete remission of the respiratory complaints, and 
the patient remains in remission at this writing (3 years). Six 
months after the discontinuation of the therapy, the patient 
achieved an SVR.
Tests conducted for the purpose of diagnosing and 
evaluating pulmonary function revealed minimum 
alterations. A high-resolution computed tomography 
scan of the chest showed signs of diffuse, possibly 
chronic, bronchial disease, with extensive thickening 
of the bronchial walls (Fig. 2). Bronchoscopy revealed 
normal morphology up to the subsegmental bronchi. 
Cytology of bronchoalveolar lavage fluid revealed abundant 
cellularity: 95% pneumocytes/alveolar macrophages and 
5% lymphocytes. Direct testing, as well as cultures for 
mycobacteria and fungi, yielded negative results. Double 
immunodiffusion and counterimmunoelectrophoresis for 
Paracoccidioides brasiliensis and Aspergillus fumigatus 
were negative. Transbronchial biopsy showed preserved 
Figure 2 - Tomographic slice: signs of diffuse, possibly chronic, bronchial 
disease with diffuse thickening of the bronchial walls.
Figure 1 - Expectoration by the patient on two distinct occasions. Note the 
aspect that mimics a bronchial segment cast (A) and the mucoid character-
istics of the material (B).
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alveolar walls with no fibrosis or significant inflammation 
and few alveolar macrophages. There was no histological 
evidence of chronic pulmonary disease, nor were there any 
granulomas or signs of neoplasms (Fig. 3). Arterial blood gas 
analysis results revealed a PaO2 of 79 mmHg, and the results 
of pulmonary function testing were within the limits of 
normality (FEV1, 83% of predicted). We concluded that there 
were no chronic pulmonary diseases or other associated 
pulmonary diagnoses that would explain the profile. 
Therefore, the established cause-and-effect relationship, 
together with the lack of factors other than the use of the 
pegylated interferon-ribavirin combination, brought us to 
the conclusion that the effects observed in this case were 
induced by the therapy against HCV.
DISCUSSION
Case reports that attribute pulmonary symptoms and 
signs to the use of interferon alpha and ribavirin have shown 
that these effects appear 2 to 12 weeks after the initiation 
of treatment. Most of the reported complaints are of fever, 
progressive dyspnea and cough. Radiological imaging 
studies detect diffuse interstitial infiltrates and opacities 
consistent with a ground-glass pattern. Pulmonary biopsies 
reveal interstitial pneumonitis, idiopathic pulmonary 
fibrosis, BOOP and sarcoidosis. In all the reported cases 
of pulmonary complications during therapy with interferon 
alpha (with the exception of a case of acute respiratory 
distress syndrome), the symptoms regressed after the 
discontinuation of the treatment.3–6,8,11
Our patient also presented symptom onset after the 
twelfth week of treatment. The predominant feature was 
cough with abundant expectoration containing bronchial 
casts. Among the hypotheses considered in the differential 
diagnosis were alveolar proteinosis and allergic bronchial 
aspergillosis. After complementary tests, such diagnoses 
were ruled out. Therefore, we considered the possibility of 
a late hypersensitivity reaction to interferon alpha, and that 
the reaction was restricted to the lungs, more specifically 
to the tracheobronchial tree, and involved the formation of 
mucous plugs. Some authors have stated that the process of 
interferon-induced exacerbation of bronchospasm symptoms 
is similar to that of asthma, with the formation of bronchial 
casts and improvement after corticosteroid therapy.
Considering that the pathogenesis of the side effects 
associated with pegylated interferon remains unclear, two 
possibilities must be considered. One is the direct toxicity of 
the drug to the lung, and the other is the activation of indirect 
toxicity mechanisms that involve immunological pathways 
(e.g., autoimmune pathways). Interferons inhibit suppressor 
T cells, alter cytotoxic T cells and induce pro-inflammatory 
cytokines. Interferons also cause the overproduction of 
fibrogenic cytokines, such as platelet-derived growth factor 
and transforming growth factor beta, thereby potentially 
inducing pulmonary fibrosis. In cases in which immunogenic 
mediation is the principal cause of the exacerbation of 
bronchospasm symptoms, there is an increase in the Th1-
type lymphocytic response and a consequent increase in the 
production of interferon gamma and interleukin-2. We also 
speculated that the stimulation of other cells or cytokines 
triggered an inflammatory cascade. In cases of interstitial 
pneumonia, the mechanism remains poorly understood. 
The suggested treatment has been the discontinuation of 
interferon alpha. However, corticosteroid therapy can also 
suppress the symptoms.
In the case described, considering the good EVR and 
the severity of the hepatic impairment, together with the 
consent of the patient, we opted to not interrupt the hepatitis 
C therapy. Empirically, corticosteroid therapy was employed 
at the lowest effective dose and only until the symptoms 
were controlled to avoid any possible immune alterations 
driven by prednisone. As a result, there was no progression 
of the symptoms, and the exacerbations were controlled. 
Immediately after the use of pegylated interferon and 
ribavirin was discontinued, there was complete remission 
of the respiratory complaints, and the patient remains 
in remission at this writing. By six months after the 
discontinuation of the therapy, the patient achieved an SVR.
This case illustrates an unexpected pulmonary-related 
adverse effect associated with the use of pegylated interferon 
and ribavirin for the treatment of hepatitis C. Despite 
being rare and reversible, the potential severity of this type 
of adverse effect suggests that the signs and symptoms 
of lung disease should be carefully evaluated in patients 
Figure 3 - Transbronchial biopsy (Hematoxylin-Eosin × 100): preserved 
alveolar walls without fibrosis or significant inflammation having only a 
few alveolar macrophages. No histological evidence of chronic lung disease, 
granulomas or neoplasms.
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under treatment with pegylated interferon and ribavirin. 
Especially in cases involving patients with a history of 
chronic lung disease, asthma or relevant smoking, we 
recommend that the initial evaluation include at least one 
chest X-ray and pulmonary function tests. When facing an 
adverse and unexpected manifestation, one should consider 
the use of corticosteroid therapy to contain the exacerbated 
inflammatory response and allow the maintenance of the 
therapy against HCV, while emphasizing that total adhesion 
to the established dose schedule is of extreme importance 
for achieving an SVR. This case and the accumulation 
of pulmonary-related adverse events described during 
therapy with the pegylated interferon-ribavirin combination 
underscore the need for pharmacovigilance, as well as the 
need to establish minimum therapeutic parameters for the 
appropriate management of such cases. 
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